Literature DB >> 8719696

The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial.

B Katz.   

Abstract

PURPOSE: We sought to characterize the dyschromatopsia of optic neuritis, to determine the type and severity of color defect present and its relation to central vision and spatial acuity, to examine changes in this dyschromatopsia over time, and to determine the applicability of Köllner's rule to patients with optic neuritis.
METHODS: We analyzed the raw data on color vision performance as assembled within the Optic Neuritis Treatment Trial (ONTT). The ONTT was designed to evaluate corticosteroids as a treatment for acute demyelinating optic neuritis and to allow long-term outcome and natural history analyses. Between July 1, 1988 and June 30, 1991, 488 patients were enrolled in this trial. All patients underwent extensive neurologic and ophthalmologic examinations including standardized testing of visual function that included testing of color vision. The ONTT population thus afforded a unique opportunity to characterize acquired dyschromatopsias in a large, homogenous, well-characterized cohort of patients with optic neuritis. We used quantitative analysis of FM-100 scores from this patient cohort to determine the severity of the dyschromatopsia, the selectivity of the dyschromatopsia (polarity of errors) and the type of dyschromatopsia (axis of confusion) by employing quadrant analysis of FM-100 scores.
RESULTS: The results of high-and low-selectivity analyses of the FM-100 data showed that during the acute phase of optic neuritis, blue/yellow, red/ green, and non-selective color defects occurred; among patients with pure defects, blue/yellow defects were more frequent than red/green defects. At 6 months after the acute event, however, analyses showed that red/green defects were more common than blue/yellow defects. Among patients with selective color defects both acutely and at 6 months, the defect was as likely to change over time as remain the same. The likelihood of persistent dyschromatopsia at 6 months was related to the severity of initial central acuity loss, but the type of dyschromatopsia present (red/green versus blue/yellow) was not.
CONCLUSIONS: Our results suggest that at the time of the acute attack of optic neuritis, the majority of selective color defects were blue/yellow defects, whereas at 6 months, more of the selective defects were red/green defects, though both types of defects (as well as nonselective defects) were seen acutely and at 6 months. Despite the rigorous inclusion criteria of the ONTT, the large number of patients we studied, correlation of color vision with visual acuity, and longitudinal follow up, this study showed that no single type of color defect was consistently associated with optic neuritis. Demyelinating optic neuritis does not obey Köllner's rule. Moreover, the type of defect present changed in some patients over the course of recovery. Thus, the type of defect may not even be consistent in individual patients as they recover. The type of defect appeared to be related to spatial vision at the time of the test, but the type of defect present at 6 months was not related to the severity of the initial visual loss. Therefore, in evaluating color defects associated with optic neuritis, the level of central visual function must be considered.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8719696      PMCID: PMC1312075     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  45 in total

1.  Visual parameters associated with recovered retrobulbar optic neuritis.

Authors:  R M Burde; P F Gallin
Journal:  Am J Ophthalmol       Date:  1975-06       Impact factor: 5.258

2.  Color vision and visually evoked response (VECP) in the recovery period of optic neuritis.

Authors:  H G Wildberger; G H van Lith
Journal:  Mod Probl Ophthalmol       Date:  1976

3.  The Optic Neuritis Treatment Trial.

Authors:  R W Beck
Journal:  Arch Ophthalmol       Date:  1988-08

4.  Chromatic, spatial, and temporal losses of sensitivity in multiple sclerosis.

Authors:  S J Dain; K W Rammohan; S C Benes; P E King-Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-03-01       Impact factor: 4.799

5.  Spatiotemporal contrast sensitivity and colour vision in multiple sclerosis.

Authors:  D Travis; P Thompson
Journal:  Brain       Date:  1989-04       Impact factor: 13.501

Review 6.  Acquired dyschromatopsias.

Authors:  W M Hart
Journal:  Surv Ophthalmol       Date:  1987 Jul-Aug       Impact factor: 6.048

7.  The dyschromatopsia of optic neuritis is determined in part by the foveal/perifoveal distribution of visual field damage.

Authors:  S E Silverman; W M Hart; M O Gordon; C Kilo
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-09       Impact factor: 4.799

8.  The visual defect in multiple sclerosis and optic neuritis. A combined psychophysical and electrophysiological investigation.

Authors:  M H Russell; I J Murray; R A Metcalfe; J J Kulikowski
Journal:  Brain       Date:  1991-12       Impact factor: 13.501

9.  Colour and luminance vision in human optic neuritis.

Authors:  K T Mullen; G T Plant
Journal:  Brain       Date:  1986-02       Impact factor: 13.501

10.  A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.

Authors:  R W Beck; P A Cleary; M M Anderson; J L Keltner; W T Shults; D I Kaufman; E G Buckley; J J Corbett; M J Kupersmith; N R Miller
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

View more
  9 in total

Review 1.  Paradigm Shifts in Ophthalmic Diagnostics.

Authors:  J Sebag; Alfredo A Sadun; Eric A Pierce
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

2.  Comparison between Hardy-Rand-Rittler 4th edition and Ishihara color plate tests for detection of dyschromatopsia in optic neuropathy.

Authors:  Ruth Huna-Baron; Yoseph Glovinsky; Zohar Habot-Wilner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-06-13       Impact factor: 3.117

3.  Colour vision defects in asymptomatic carriers of the Leber's hereditary optic neuropathy (LHON) mtDNA 11778 mutation from a large Brazilian LHON pedigree: a case-control study.

Authors:  P A Quiros; R J Torres; S Salomao; A Berezovsky; V Carelli; J Sherman; F Sadun; A De Negri; R Belfort; A A Sadun
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

4.  Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis.

Authors:  Erin E Longbrake; Samantha Lancia; Nhial Tutlam; Kathryn Trinkaus; Robert T Naismith
Journal:  Mult Scler Relat Disord       Date:  2016-11-04       Impact factor: 4.339

5.  Optic neuritis, its differential diagnosis and management.

Authors:  Hedieh Hoorbakht; Farid Bagherkashi
Journal:  Open Ophthalmol J       Date:  2012-07-24

6.  Color vision versus pattern visual evoked potentials in the assessment of subclinical optic pathway involvement in multiple sclerosis.

Authors:  Fatih C Gundogan; Ahmet Tas; Salih Altun; Oguzhan Oz; Uzeyir Erdem; Gungor Sobaci
Journal:  Indian J Ophthalmol       Date:  2013-03       Impact factor: 1.848

7.  Color blindness among multiple sclerosis patients in Isfahan.

Authors:  Vahid Shaygannejad; Khodayar Golabchi; Alireza Dehghani; Fereshteh Ashtari; Sepehr Haghighi; Mahsa Mirzendehdel; Majid Ghasemi
Journal:  J Res Med Sci       Date:  2012-03       Impact factor: 1.852

8.  Auditory and visual health after ten years of exposure to metal-on-metal hip prostheses: a cross-sectional study follow up.

Authors:  Jennifer R Prentice; Christopher S Blackwell; Naz Raoof; Paul Bacon; Jaydip Ray; Simon J Hickman; J Mark Wilkinson
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

Review 9.  Retinal Ganglion Cells-Diversity of Cell Types and Clinical Relevance.

Authors:  Ungsoo Samuel Kim; Omar A Mahroo; John D Mollon; Patrick Yu-Wai-Man
Journal:  Front Neurol       Date:  2021-05-21       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.